Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamikibart in Diabetic Macular Edema
NCT05151731Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2021
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of vamikibart in diabetic macular edema (DME) (4 arms), sponsored by Roche. Primary endpoint: Best-Corrected Visual Acuity at 48 weeks. Started Dec 2021; status: completed.
02
Drugs
vamikibart
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05151731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05151731.